Skip to main content

Table 2 Associations between LY6D expression and clinicopathological characteristics in Cohort III

From: Lymphocyte antigen 6 superfamily member D is a marker of urothelial and squamous differentiation: implications for risk stratification of bladder cancer

LY6D expression TURB Cystectomy
0 1 2 P-value 0 1 2 P-value
n(%) 74 (51.4) 42 (29.2) 28 (19.4)   56 (55.4) 32 (31.7) 13 (12.9)  
Age
 Mean, median 67.8, 69.7 69.6, 70.6 69.6, 72.5 0.421 69.7, 72.6 70.3, 70.6 74.0, 74.3 0.288
 range 38.7–83.3 45.6–90.0 48.0–81.7   38.7–82.7 50.3–81.7 57.6–83.3  
Sex
 Male 57 (77) 37 (88.1) 20 (71.4) 0.878 44 (78.6) 26 (81.3) 9 (69.2) 0.644
 Female 17 (23) 5 (11.9) 8 (28.6)   12 (21.4) 6 (18.8) 4 (30.8)  
Preoperative T-stage
 T2 44 (59.5) 20 (47.6) 12 (42.9) 0.018 26 (46.4) 16 (50.0) 7 (53.8) 0.677
 T3 26 (35.1) 14 (33.3) 10 (35.7)   21 (37.5) 14 (43.8) 4 (30.8)  
 T4 4 (5.4) 8 (19.0) 6 (21.4)   9 (16.1) 2 (6.3) 2 (15.4)  
Postoperative T-stage
 pT0/pTa/CIS only 26 (35.1) 14 (33.3) 4 (14.3) 0.093 7 (12.5)a 5 (15.6) 2 (15.4) 0.349
 pT1 7 (9.5) 4 (9.5) 2 (7.1)   6 (10.7) 4 (12.5) 1 (7.7)  
 pT2 14 (18.9) 8 (19.0) 7 (25.0)   11 (19.6) 6 (18.8) 3 (23.1)  
 pT3 19 (25.7) 10 (23.8) 13 (46.4)   20 (35.7) 14 (43.8) 7 (53.8)  
 pT4 8 (10.8) 6 (14.3) 2 (7.1)   12 (21.4) 3 (9.4) 0 (0.0)  
N-stage
 N0 51 (68.9) 31 (73.8) 20 (71.4) 0.818 31 (55.4) 23 (71.9) 11 (84.6) 0.017
 N1 8 (10.8) 5 (11.9) 3 (10.7)   7 (12.5) 3 (9.4) 2 (15.4)  
 N2 8 (10.8) 4 (9.5) 1 (3.6)   10 (17.9) 2 (6.3) 0 (0.0)  
 N3 7 (9.5) 2 (4.8) 4 (14.3)   8 (14.3) 4 (12.5) 0 (0.0)  
LVI in cystectomy
 No 46 (93.9) 26 (89.7) 23 (100.0) 0.448 44 (89.8) 26 (92.9) 12 (100.0) 0.253
 Yes 3 (6.1) 3 (10.3) 0 (0.0)   5 (10.2) 2 (7.1) 0 (0.0)  
Missing 25 13 5   7 4 1  
CIS in TURB specimens
 Not found 69 (93.2) 34 (81.0) 26 (92.9) 0.532 49 (87.5) 28 (87.5) 13 (100.0) 0.299
 Found 5 (6.8) 8 (19.0) 2 (7.1)   7 (12.5) 4 (12.5) 0 (0.0)  
CIS in cystectomy specimens
 Not found 60 (81.1) 34 (81.0) 25 (89.3) 0.396 40 (71.4) 25 (78.1) 13 (100.0) 0.039
 Found 14 (18.9) 8 (19.0) 3 (10.7)   16 (28.6) 7 (21.9) 0 (0.0)  
NAC
 No 39 (52.7) 21 (50.0) 19 (67.9) 0.262 40 (71.4) 22 (68.8) 10 (76.9) 0.840
 Yes 35 (47.3) 21 (50.0) 9 (32.1)   16 (28.6) 10 (31.3) 3 (23.1)  
  1. aCystectomy specimens with tumour stage pT0 were excluded from the analysis
  2. Correlations with grade were not analyzed since all 145 TURB tumours were high-grade and
  3. only 3/104 assessable cystectomy tumours were low-grade
  4. Correlations with M-stage were not analyzed since only 3 cases were M1
  5. CIS Carcinoma in situ, NAC neoadjuvant chemotherapy
  6. 0 = Negative LY6D expression, 1 = ≤ 50% positive LY6D expression, 2 = > 50% LY6D expression
  7. P-value < 0.05 is considered significant